Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Stomach Neoplasms 2Peritoneal Neoplasms 2Mesothelioma, Malignant 2Mesothelioma 2Colonic Neoplasms 2Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Pelvic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorder, Chronic, with Eosinophilia 1Liposarcoma 1Fallopian Tube Neoplasms 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Abdominal Neoplasms 1

Interventions

Carboplatin 24Pemetrexed 18Cisplatin 17Paclitaxel 14pembrolizumab 13Gemcitabine 8osimertinib 7durvalumab 6Docetaxel 6Nivolumab 5Erlotinib Hydrochloride 5130-nm albumin-bound paclitaxel 5capmatinib 3brigatinib 3anlotinib 3Gefitinib 3Drug Therapy 3vosaroxin 2volociximab 2sintilimab 2pralsetinib 2ensartinib 2atezolizumab 2aflibercept 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Oncolytic Virotherapy 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Cytoreduction Surgical Procedures × Thoracic × Clear all
NCT05375825 2024-02-02

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
MyeloidOther solid neoplasmThoracic

Myeloproliferative Disorder, Chronic, with Eosinophilia, Mesothelioma, Malignant, Carcinoma, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡